Original Articles
Vol. 15 No. 1 (2023): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
https://doi.org/10.4084/MJHID.2023.001

BETTER OUTCOME OF HIGH-DOSE CEFTAZIDIME IN HEMATO – ONCOLOGICAL PATIENTS WITH INFECTIONS CAUSED BY EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: September 8, 2022
Accepted: December 5, 2022
Published: December 31, 2022
1473
Views
1044
Downloads
401
HTML
ceftazidime, neutropenia;, XDR P. aeruginosa infection

Authors

Alzbeta Zavrelova
a:1:{s:5:"en_US";s:131:"4th Department of Internal Medicine – Haematology, University Hospital and Charles University Faculty of Medicine, Hradec Kralove";}, Czechia.
Jakub Radocha
jakub.radocha@fnhk.cz
4th Department of Internal Medicine – Haematology, University Hospital and Charles University Faculty of Medicine, Hradec Kralove, Czechia.
Pavla Paterova
Department of Clinical Microbiology, University Hospital and Charles University Faculty of Medicine, Hradec Kralove , Czechia.
Pavel Zak
4th Department of Internal Medicine – Haematology, University Hospital and Charles University Faculty of Medicine, Hradec Kralove, Czechia.
Benjamin Visek
4th Department of Internal Medicine – Haematology, University Hospital and Charles University Faculty of Medicine, Hradec Kralove, Czechia.
Martin Sima
Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Czechia.

Background: P. aeruginosa sepsis in immunocompromised patients is serious complication of cancer treatment, especially in case of XDR pathogen.

The purpose of the study is to evaluate the efficacy of high-dose ceftazidime in treatment of XDR P. aeruginosa infection and to compare it with the conventionally treated cohort in hemato-oncological patients.

Methods: We identified 27 patients with XDR P. aeruginosa infection during the 2008-2018 period, 16 patients served as a conventionally treated cohort with antipseudomonal beta-lactam antibiotic in standard dose (cohort A), and 11 patients were treated with high-dose ceftazidime (cohort B).  Most of the patients were neutropenic and under active treatment for their cancer in both cohorts.

Results: Mortality and related mortality were statistically significantly better for cohort B compared to cohort A,  it was  18.2% and 9.1% for cohort B and 68.8% and 68.8% for cohort A, respectively. More patients in cohort A needed mechanical ventilation and renal replacement therapy, 75% and 50% for cohort A and 27.3% and 9.9% for cohort B, respectively.  It corresponded well with the worst SOFA in cohort A in comparison to cohort B, 16 versus 7 respectively. Reversible neurotoxicity was seen only in two patients in cohort B.

Conclusion: Ceftazidime in high doses is a very potent ATB for the treatment of XDR P. aeruginosa infections in neutropenic cancer with acceptable toxicity.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

This work was supported by the programme Cooperatio, research area ONCO. Supported by MH CZ - DRO (UHHK, 00179906).

How to Cite



“BETTER OUTCOME OF HIGH-DOSE CEFTAZIDIME IN HEMATO – ONCOLOGICAL PATIENTS WITH INFECTIONS CAUSED BY EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA” (2022) Mediterranean Journal of Hematology and Infectious Diseases, 15(1), p. e2023001. doi:10.4084/MJHID.2023.001.
Copyright (c) 2022 Alzbeta Zavrelova, Jakub Radocha, Pavla Paterova, Pavel Zak, Benjamin Visek, Martin Sima Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.